당화혈색소 검사 시장 : 검사 유형별, 제품 유형, 기술, 적응증, 최종 사용자별 예측(2026-2032년)

The Glycated Hemoglobin Testing Market is projected to grow by USD 3.66 billion at a CAGR of 7.76% by 2032.

Glycated hemoglobin testing, widely known as HbA1c testing, is a cornerstone of diabetes diagnosis and long-term glycemic monitoring because it reflects average blood glucose exposure over roughly the prior two to three months. The World Health Organization and the American Diabetes Association recognize HbA1c of 6.5% or higher, when measured with standardized methods, as a diagnostic threshold for diabetes.

Demand is being reinforced by the global diabetes burden, with WHO reporting that more than 800 million people were living with diabetes in 2022. Adoption is also supported by broader screening, laboratory automation, point-of-care HbA1c testing, and quality standardization through NGSP and IFCC-aligned methods that improve comparability across laboratories and care settings.

Transformative Shifts in the HbA1c Testing Landscape

The HbA1c testing landscape is shifting from periodic central-laboratory testing toward connected, decentralized, and patient-centered models. Primary care clinics, pharmacies, and community health programs are increasingly using rapid HbA1c platforms to support earlier therapy adjustment, improve diabetes screening workflows, and reduce follow-up delays.

At the same time, clinical use is becoming more nuanced. Continuous glucose monitoring provides real-time glucose variability data, but HbA1c remains essential for diabetes diagnosis, risk stratification, payer reporting, and longitudinal outcomes assessment. Instrument developers and laboratory networks are responding with smaller analyzers, improved sample handling, automated calibration, and stronger quality-control systems.

Cumulative Impact of Artificial Intelligence on HbA1c Testing

Artificial intelligence is creating cumulative value across the HbA1c testing workflow rather than replacing the assay itself. AI-enabled laboratory information systems can flag abnormal result patterns, identify patients overdue for testing, support reflex testing protocols, and improve population-level diabetes management by linking HbA1c values with longitudinal clinical records.

In instrument operations, predictive maintenance and automated quality-control analytics can reduce downtime and help laboratories maintain compliance with accreditation expectations. In clinical care, AI models that combine HbA1c with medications, comorbidities, kidney function, cardiovascular risk, and social determinants can improve risk stratification while requiring strong governance, transparent validation, and bias monitoring.

Key Regional Insights Across Global HbA1c Testing

Asia-Pacific is a major demand center for glycated hemoglobin testing due to large diabetes populations in China, India, Japan, Australia, and South Korea, alongside expanding diagnostic infrastructure, urban primary care networks, and rising use of automated laboratory systems. North America remains highly mature, supported by routine diabetes screening, established reimbursement pathways, CLIA-waived point-of-care HbA1c testing in the United States, and strong adoption of high-throughput analyzers across hospital and reference laboratories.

Latin America is advancing through public health screening initiatives and private laboratory networks, especially in Brazil and Mexico, where access and affordability remain central to adoption. Europe benefits from standardized laboratory quality frameworks, national diabetes programs, and widespread use of accredited diagnostic pathways. The Middle East is investing in chronic disease management amid high metabolic disease prevalence, particularly across Gulf health systems, while Africa shows long-term potential as diabetes awareness increases but requires affordable testing, stronger supply chains, workforce expansion, and improved access outside major urban centers.

Key Group Insights for HbA1c Testing Adoption

ASEAN demand is supported by urbanization, rising obesity, and stronger primary care investment, with point-of-care HbA1c platforms improving access beyond tertiary hospitals and supporting earlier diabetes intervention. GCC markets are shaped by high diabetes prevalence, preventive health strategies, national screening programs, and premium diagnostic infrastructure across Gulf health systems.

The European Union benefits from harmonized quality expectations, accredited laboratory systems, and broad public reimbursement, while BRICS countries combine large patient pools with expanding domestic diagnostics capacity and growing chronic disease programs. G7 markets lead in automation, informatics, quality assurance, and guideline-driven diabetes testing. NATO countries broadly reflect strong hospital networks, regulated procurement standards, and established laboratory capacity, although HbA1c adoption varies by national reimbursement policies, laboratory consolidation, and primary care access.

Key Country Insights Shaping HbA1c Testing Demand

The United States leads through guideline-based diabetes care, high routine testing use, established reimbursement, and a strong point-of-care ecosystem, while Canada emphasizes quality-assured laboratory testing within publicly funded care. Mexico and Brazil are expanding access through primary care screening, public health programs, and private diagnostics, though affordability, geographic access, and reagent availability remain important for consistent HbA1c testing.

In Europe, the United Kingdom, Germany, France, Italy, and Spain benefit from structured diabetes care pathways, accredited laboratories, and established chronic disease monitoring, while Russia relies on broad regional laboratory networks to support testing access across diverse geographies. China and India represent substantial testing demand driven by large diabetes populations, urbanization, and expanding healthcare infrastructure. Japan and South Korea emphasize precision, automation, laboratory quality, and aging-population management, while Australia supports standardized chronic disease monitoring through established primary care pathways and national diabetes care practices.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize assay accuracy, NGSP/IFCC traceability, lot-to-lot consistency, and robust quality-control documentation, particularly as HbA1c testing expands beyond central laboratories into primary care and community settings. Product portfolios should address both high-throughput laboratories and decentralized sites with clear operator training, intuitive workflows, connectivity, regulatory support, and service reliability.

Organizations should also invest in interoperability with electronic health records, AI-enabled patient recall tools, and education around HbA1c limitations in anemia, hemoglobin variants, chronic kidney disease, pregnancy, altered red blood cell turnover, and recent transfusion. Regional pricing, reagent availability, local technical support, and resilient distribution networks will be critical differentiators in emerging markets and underserved care settings.

Research Methodology

This executive summary is built from a structured review of clinical guidelines, public health datasets, regulatory references, laboratory standardization frameworks, peer-reviewed evidence, and health-system indicators. Key sources include WHO diabetes data, ADA Standards of Care, NGSP and IFCC standardization principles, and regional diagnostic policy references.

The methodology evaluates demand conditions through disease prevalence, screening policy, reimbursement structures, installed diagnostic capacity, point-of-care adoption, laboratory accreditation, digital health readiness, and technology integration. Insights are triangulated across regional, economic group, and country-level evidence to support practical strategic interpretation without relying on market estimation, market sizing, market share, or forecasting.

Conclusion

Glycated hemoglobin testing remains indispensable to diabetes care because it provides standardized, clinically actionable evidence of long-term glycemic control. Even as continuous glucose monitoring expands, HbA1c continues to anchor diabetes diagnosis, therapy assessment, quality metrics, risk stratification, and population health programs.

Future advancement will depend on reliable decentralization, AI-supported workflows, affordability, quality standardization, and improved access in underserved settings. Organizations that combine analytical quality with digital integration, operator simplicity, and region-specific commercialization strategies will be best positioned to strengthen HbA1c testing access and clinical value.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Glycated Hemoglobin Testing Market, by Test Type

• 7.1. Laboratory-Based Testing
• 7.2. Point-of-Care (POC) Testing

8. Glycated Hemoglobin Testing Market, by Product Type

• 8.1. Instruments
  • 8.1.1. Bench-Top Analyzers
  • 8.1.2. Portable Analyzers
• 8.2. Reagents & Consumables

9. Glycated Hemoglobin Testing Market, by Technology

• 9.1. Boronate Affinity Chromatography
• 9.2. Electrophoresis
• 9.3. Enzymatic Assays
• 9.4. High-Performance Liquid Chromatography (HPLC)
• 9.5. Immunoassay Methods

10. Glycated Hemoglobin Testing Market, by Indication

• 10.1. Diabetes Diagnosis
• 10.2. Routine Monitoring

11. Glycated Hemoglobin Testing Market, by End User

• 11.1. Diagnostic Laboratories
• 11.2. Home Care
• 11.3. Hospital & Clinics
• 11.4. Research Institutions

12. Glycated Hemoglobin Testing Market, by Region

• 12.1. Asia-Pacific
• 12.2. North America
• 12.3. Latin America
• 12.4. Europe
• 12.5. Middle East
• 12.6. Africa

13. Glycated Hemoglobin Testing Market, by Group

• 13.1. ASEAN
• 13.2. GCC
• 13.3. European Union
• 13.4. BRICS
• 13.5. G7
• 13.6. NATO

14. Glycated Hemoglobin Testing Market, by Country

• 14.1. United States
• 14.2. Canada
• 14.3. Mexico
• 14.4. Brazil
• 14.5. United Kingdom
• 14.6. Germany
• 14.7. France
• 14.8. Russia
• 14.9. Italy
• 14.10. Spain
• 14.11. China
• 14.12. India
• 14.13. Japan
• 14.14. Australia
• 14.15. South Korea

15. Competitive Landscape

• 15.1. Market Concentration Analysis, 2025
  • 15.1.1. Concentration Ratio (CR)
  • 15.1.2. Herfindahl Hirschman Index (HHI)
• 15.2. Recent Developments & Impact Analysis, 2025
• 15.3. Product Portfolio Analysis, 2025
• 15.4. Benchmarking Analysis, 2025

16. Company Profiles

• 16.1. Abbott Laboratories Inc.
• 16.2. F. Hoffmann-La Roche AG
• 16.3. Danaher Corporation
• 16.4. Siemens Healthineers AG
• 16.5. Bio-Rad Laboratories, Inc.
• 16.6. ARKRAY, Inc.
• 16.7. Tosoh Corporation
• 16.8. Sysmex Corporation
• 16.9. EKF Diagnostics Holdings plc
• 16.10. Nova Biomedical Corporation
• 16.11. Randox Laboratories Ltd.
• 16.12. DiaSys Diagnostic Systems GmbH
• 16.13. Sinocare Inc.
• 16.14. Sebia S.A.
• 16.15. HUMAN Gesellschaft fur Biochemica und Diagnostica mbH
• 16.16. TaiDoc Technology Corporation
• 16.17. Diazyme Laboratories, Inc.
• 16.18. Daiichi Biotech Services Sdn. Bhd.
• 16.19. Lifotronic Technology Co., Ltd.
• 16.20. Metropolis Healthcare Limited
• 16.21. Quest Diagnostics
• 16.22. SAKAE Co., Ltd.
• 16.23. Trinity Biotech Plc.